Patents for A61P 35 - Antineoplastic agents (221,099)
05/2002
05/10/2002CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
05/10/2002CA2424932A1 Cd36 as a heat shock protein receptor and uses thereof
05/10/2002CA2395324A1 Expression potentiator for protein synthesis regulatory gene
05/09/2002WO2002036153A1 Expression potentiator for protein synthesis regulatory gene
05/09/2002US20020055666 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
05/09/2002US20020055643 Tubulin binding ligands and corresponding prodrug constructs
05/09/2002US20020055632 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction
05/09/2002US20020055625 Members of TNF and TNFR families
05/09/2002US20020055615 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
05/09/2002US20020055526 Modulators of SKCa, IKCa and BKCa channels.
05/09/2002US20020055518 Polyoxyethylated hydroxyesters of rapamycin useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.
05/09/2002US20020055510 Useful in the treatment of cancer.
05/09/2002US20020055489 Interleukin-12 inducer and medical composition
05/09/2002US20020055483 Treating hepatitus B, C and D; AIDS; antiproliferative agents
05/09/2002US20020055482 Molecular constructs with a carcinoembryonic antigen (cea) transcriptional regulatory sequence
05/09/2002US20020055479 Treating type 2 diabetes, metabolic disorders, obesity and cancer.
05/09/2002US20020055476 RAMPs are small proteins that transport calcitonin-receptor-like proteins to the plasma membrane; drug screening
05/09/2002US20020055462 Use
05/09/2002US20020055163 Amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides; useful in the development of human therapeutics and diagnostic formulations
05/09/2002US20020055160 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/09/2002US20020055159 23680,a novel human aminotransferase and uses therefor
05/09/2002US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies
05/09/2002US20020055140 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
05/09/2002US20020054924 Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
05/09/2002US20020054916 Comprising ceruloplasmin and a serum-derived composition (SDF) having a low molecular weight, electrically charged at acidic pH and having absorption at 280 mn, capable of inducing terminal cell differentiation of leukemic cells
05/09/2002US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent
05/09/2002US20020054900 Barrier layer positioned over composite layer and being of thickness adequate to provide controlled release of bioactive agent, barrier layer being applied by low energy plasma polymerization
05/09/2002US20020054885 Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
05/09/2002US20020054881 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites
05/09/2002US20020054869 Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
05/09/2002US20020054868 Bacterial strain, processes plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
05/09/2002US20020054867 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract
05/09/2002US20020054866 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
05/09/2002US20020054863 Method of treating cancerous tumors with a dendritic-platinate drug delivery system and a process for preparing that system
05/09/2002US20020054850 Monoterpenes and sesquiterpenes as chemotherapeutic sensitizers and radiation sensitizers
05/08/2002EP1203827A2 Polymorphisms in the human KDR gene
05/08/2002EP1203819A2 Anti-inflammatory vectors
05/08/2002EP1203766A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
05/08/2002EP1203761A2 Calcium receptor-active compounds
05/08/2002EP1203101A1 Ppar delta links apc to chemopreventive drugs
05/08/2002EP1203081A2 Human intracellular signaling molecules
05/08/2002EP1203025A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND $g(b)1 INTEGRINS
05/08/2002EP1203024A1 Human tumor necrosis factor receptors tr13 and tr14
05/08/2002EP1203023A1 Pgpcr-3 polypeptides and dna sequences thereof
05/08/2002EP1203018A1 26 human prostate and prostate cancer associated proteins
05/08/2002EP1203015A2 Human chaperone proteins
05/08/2002EP1203013A1 Kinase blocking polypeptides and uses thereof
05/08/2002EP1203010A1 Antisense modulation of fadd expression
05/08/2002EP1203007A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins
05/08/2002EP1203005A2 25 human secreted proteins
05/08/2002EP1203004A1 HIGH AFFINITY TGF$g(g) NUCLEIC ACID LIGANDS AND INHIBITORS
05/08/2002EP1202994A1 New compounds
05/08/2002EP1202993A2 Phenanthroline-7-one derivatives and their therapeutic uses
05/08/2002EP1202992A2 Ascididemin derivatives and their therapeutic applications
05/08/2002EP1202988A2 Novel integrin receptor antagonists
05/08/2002EP1202980A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
05/08/2002EP1202974A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
05/08/2002EP1202961A1 Arylsulfonamido-substituted hydroxamic acid derivatives
05/08/2002EP1202749A2 Enzyme catalyzed anti-infective therapeutic agents
05/08/2002EP1202748A2 Polycation-based bioconjugates
05/08/2002EP1202747A1 Sustained release drug dispersion delivery device
05/08/2002EP1202746A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
05/08/2002EP1202736A1 Nicotine in therapeutic angiogenesis and vasculogenesis
05/08/2002EP1202735A2 Method of cancer treatment
05/08/2002EP1202734A1 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
05/08/2002EP1202733A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
05/08/2002EP1202730A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer
05/08/2002EP1202723A2 Use of anti-muscarinic agents for treating skin disorders
05/08/2002EP1202718A2 Substituted guanidines for the treatment of cancer and pain
05/08/2002EP0998299A4 ISOLATED PEPTIDES WHICH COMPLEX WITH HLA-Cw*16 MOLECULES, AND USES THEREOF
05/08/2002EP0923585B1 Phosphinate based inhibitors of matrix metalloproteases
05/08/2002EP0888301A4 Mcbi analogs of cc-1065 and the duocarmycins
05/08/2002EP0789783B1 Antigen binding peptides (abtides) from peptide libraries
05/08/2002DE10055701A1 Organ-, cancer- or leukemia-specific liposomes, useful for targeted drug delivery, prepared using glycolipid component with a terminal oligosaccharide portion identical with the haptens of target body cells
05/08/2002DE10055700A1 Elimination of cancer or leukemia cells using active cell-destroying viruses having oligosaccharide haptens corresponding to the malignant cells
05/08/2002DE10054337A1 Phenanthridinderivate und Phenanthridin enthaltende antitumorale Arzneimittel Phenanthridine derivatives and phenanthridine-containing antitumor drug
05/08/2002CN1348497A 载体 Carrier
05/08/2002CN1348462A Novel LHRH-antagonists with improved solubility characteristics
05/08/2002CN1348460A Acetal Benzylmaltosides as inhibitors of smooth muscle cell proliferation
05/08/2002CN1348455A Pyrazolobenzodiazepines as CDK2 inhibitors
05/08/2002CN1348447A 4,5-diaryl-3(i(2H))-furanone derivatives as cyclooxygenase-2 inhibitors
05/08/2002CN1348444A 丝氨酸蛋白酶抑制剂 Serine protease inhibitors
05/08/2002CN1348436A Novel ligands of nuclear receptors PPAR's
05/08/2002CN1348383A Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same
05/08/2002CN1348375A Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
05/08/2002CN1348370A Cyclic protein tyrosine kinase inhibitors
05/08/2002CN1348363A Novel pharmaceutical salt form
05/08/2002CN1348362A Magnetically responsive composition
05/08/2002CN1347881A 法呢基蛋白转移酶抑制剂 Farnesyl protein transferase inhibitor
05/08/2002CN1347874A Application of small dosage of aminoguanidine in anti-senility and preventing and treating senile diseases
05/08/2002CN1347865A Antineoplastic compound and its prepn and pharmaceutical use
05/08/2002CN1084333C Novel artemisine compounds their producing process and pharmaceutical composition containing them
05/08/2002CN1084209C High polymer antineoplastic guide medicine and preparation thereof
05/08/2002CN1084200C Anticancer pill and its preparing process
05/08/2002CN1084187C Method for preparing anti-cancer medicine using beta-element as main effective ingredient, and its composition
05/07/2002US6384259 Heat resistant, sterile dosage suitable for reconstitution with a vehicle into an injectible, particle-free product for parenteral administration
05/07/2002US6384230 2,6-dimethyl-5-((4-ethoxyphenyl)-methoxy)-7-(2-methylthiazol-4-yl)hepta -2,6-dienoic acid ethyl ester from malic acid, wittig reaction with 2-methyl-4-thiazolylmethyl triphenyl phosphonium bromide; intermediates for epothilone a or b
05/07/2002US6384225 Intermediates in the preparation of substituted chroman derivatives
05/07/2002US6384202 Cell-specific active compounds regulated by the cell cycle
05/07/2002US6384191 Receptors for fibroblast growth factors